Table 1.
Prospective trials of monoclonal antibodies in T cell non-Hodgkin lymphoma (T-NHL).
| Agent | Combination | Phase | Lymphoma Subtypes | No. of Patients | Clinical Setting | ORR (%) | CR/PR Rate (%) | Location | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| Alemtuzumab | - | II | MF; SS | 22 | R/R | 55 | 32/23 | Europe | [31] |
| - | II | PTCL | 14 | R/R | 36 | 21/14 | Europe | [32] | |
| - | II | MF; SS | 39 | R/R | 51 | 18/33 | Europe | [33] | |
| - | II | PTCL; MF | 10 | R/R | 60 | 20/40 | Europe | [34] | |
| DHAP | II | PTCL | 24 | R/R | 50 | 21/29 | South Korea | [35] | |
| CHOP-21 | II | PTCL | 20 | newly diagnosed | 80 | 65/15 | South Korea | [36] | |
| CHOP-28 | II | PTCL | 24 | newly diagnosed | 75 | 71/4 | Europe | [37] | |
| CHOP-14 | II | PTCL | 20 | newly diagnosed | 90 | 60/50 | Europe | [38] | |
| SGN-30 | - | II | C-ALCL; LyP; MF | 23 | R/R | 70 | 43/26 | USA | [39] |
| - | II | ALCL | 41 | R/R | 17 | 5/12 | USA | [40] | |
| Brentuximab vedotin | - | II | ALCL | 58 | R/R | 86 | 57/27 | Worldwide | [41,42] |
| - | II | MF SS | 32 | R/R | 70 | 3/67 | USA | [43] | |
| - | I | PTCL; AITL | 35 | R/R | 41 | 23/18 | USA | [44] | |
| CHOP-21 (sequential) | I | ALCL | 13 | newly diagnosed | 85 | 62/23 | Worldwide | [45] | |
| CHP-21 (combination) | I | ALCL; PTCL-NOS; ATL; AITL | 26 | newly diagnosed | 100 | 88/12 | Worldwide | [45,46] | |
| - | III | pcALCL; MF | 66 | R/R | 67 | 16/51 | Worldwide | [47] | |
| Mogamulizumab | - | II | ATL | 27 | R/R | 50 | 30/NR | Japan | [48] |
| - | I/II | MF; SS | 38 | R/R | 37 | 8/29 | USA | [49] | |
| - | II | PTCL; CTCL | 37 | R/R | 35 | 14/21 | Japan | [50] | |
| - | III | MF | 105 | R/R | 21 | NR | Europe | [51] | |
| - | III | SS | 81 | R/R | 37 | NR | Europe | [51] |
Note: ALCL, anaplastic large cell lymphoma; AITL, angioimmunoblastic T cell lymphoma; ATL, adult T cell leukemia/lymphoma; C-ALCL, cutaneous ALCL; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; CR, complete response; CTCL, cutaneous T cell lymphoma; DHAP, dexamethasone high-dose cytarabine cisplatin; LyP, lymphomatoid papulosis; MF, mycosis fungoides; NR, not reported; ORR, overall response rate; pcALCL, primary cutaneous ALCL; PR, partial response; PTCL-NOS, peripheral T cell lymphoma-not otherwise specified; R/R, relapsed/refractory; SS, Sézary syndrome.